Long-term Survival Outcomes of Undifferentiated Embryonal Sarcoma of the Liver: a Pooled Analysis of 308 Patients.

Zhiyong Wu,Youzhu Wei,Zhibin Cai,Yanming Zhou
DOI: https://doi.org/10.1111/ans.15684
IF: 1.7
2020-01-01
ANZ Journal of Surgery
Abstract:BACKGROUND:Treatment of undifferentiated embryonal sarcoma of the liver (UESL) is a great clinical challenge due to its rarity. This study aims to examine the long-term survival of UESL patients after treatment using different therapeutic modalities.METHODS:A pooled analysis of individual data was performed on all UESL patients obtained from literature search (n = 307) and our institution (n = 1).RESULTS:The 5-year overall survival rate of the 308 patients was 65.8%, 70% for partial hepatectomy group (n = 271), 78.9% for liver transplantation group (n = 14) and 6.6% for nonsurgical treatment group (n = 23). For patients receiving partial hepatectomy, paediatric patients, radical resection and combined chemotherapy were independent predictors for improved survival.CONCLUSION:Radical hepatectomy combined chemotherapy should be considered as the preferred treatment option for USEL. Liver transplantation appears to be a reasonable alternative for unresectable disease.
What problem does this paper attempt to address?